MIRA Pharmaceuticals, Inc. (MIRA)
NASDAQ: MIRA · Real-Time Price · USD
1.060
+0.060 (6.00%)
At close: Dec 20, 2024, 4:00 PM
1.080
+0.020 (1.89%)
After-hours: Dec 20, 2024, 5:55 PM EST
MIRA Pharmaceuticals Employees
The last reported number of employees for MIRA Pharmaceuticals was 3.
Employees
3
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,746,780
Market Cap
17.55M
No historical employees data available.
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 45 |
| Inspira Technologies Oxy B.H.N. | 42 |
| IN8bio | 31 |
| Palatin Technologies | 30 |
| MEI Pharma | 28 |
| Unity Biotechnology | 19 |
| XTL Biopharmaceuticals | 7 |
| Aprea Therapeutics | 7 |
MIRA News
- 2 days ago - MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development - Accesswire
- 11 days ago - MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End - Accesswire
- 4 weeks ago - MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site - Accesswire
- 7 weeks ago - MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain - Accesswire
- 2 months ago - MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study - Accesswire
- 3 months ago - MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024 - Accesswire
- 3 months ago - MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025 - Accesswire
- 3 months ago - MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA - Accesswire